Dianthus Therapeutics vs Cartesian Therapeutics
DNTH and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNTH and RNAC compare
Dianthus Therapeutics is the larger company, worth 24 times as much as Cartesian Therapeutics ($5.0B against $208M).
Dianthus Therapeutics scores higher on the StockData Score (7 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNTH | RNAC |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $208M |
| Share price | $89.30 | $6.89 |
| Change, 1 year | 144% | −12.5% |
| Change, 5 years | −16.6% | −92.8% |
| Beta (5Y) | 1.44 | 1.42 |
| Employees | 92 | 75 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 203× |
| P/B | 4.0× | – |
| FCF yield | – | −43.1% |
| Growth | ||
| Revenue growth, 5Y average | – | −30.0% |
| Profitability | ||
| Operating margin | – | −15541% |
| Net margin | – | −12435% |
| FCF margin | – | −8770% |
| Return on equity | −22.6% | – |
| Return on invested capital | −22.2% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 30.02 (better) | 8.38 |
| Altman Z-score | 85.71 (better) | −5.09 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 118% | 29.3% |
| Held by insiders | 9.1% | 55.7% |
| Insider net buying, 12 months | −$63.8M | −$52.9K (better) |
| Short interest, % of float | 18.2% | 14.3% |
Go deeper
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
- RNAC stock overview
- RNAC income statement
- RNAC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.